Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 11/20 | 0.85 |
| ▸ | VCP | P55072 | 2/20 | 0.66 |
| ▸ | TLR4 | O00206 | 6/20 | 0.58 |
| ▸ | TLR2 | O60603 | 6/20 | 0.58 |
| ▸ | ABL1 | P00519 | 1/20 | 0.53 |
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
| ▸ | ABL2 | P42684 | 1/20 | 0.53 |
| ▸ | TERT | O14746 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8625808 | 0.79 | FBP1 (1.00) | FBP1VCPTLR4TLR2MAOB | |
| SCHEMBL8625803 | 0.79 | FBP1 (1.00) | FBP1VCPTLR4TLR2MAOB | |
| SCHEMBL1027331 | 0.79 | FBP1 (1.00) | FBP1VCPTLR4TLR2ABL1 | |
| SCHEMBL1937312 | 0.79 | FBP1 (1.00) | FBP1VCPTLR4TLR2ABL1 | |
| SCHEMBL1027330 | 0.79 | FBP1 (1.00) | FBP1VCPTLR4TLR2ABL1 | |
| SCHEMBL527535 | 0.79 | FBP1 (1.00) | FBP1VCPTLR4TLR2MAOA | |
| SCHEMBL2073418 | 0.79 | FBP1 (1.00) | FBP1VCPTLR4TLR2ABL1 | |
| SCHEMBL12720865 | 0.79 | FBP1 (1.00) | FBP1VCPTLR4TLR2ABL1 | |
| SCHEMBL527534 | 0.79 | FBP1 (1.00) | FBP1VCPTLR4TLR2MAOA | |
| SCHEMBL6806353 | 0.79 | FBP1 (0.75) | FBP1VCPTLR4TLR2ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1497294-B1 | 1,2,3,4,7,8-HEXAHYDRO-6 i H /i - 1,4 DIAZEPINO 6,7 ,1- i 1J /i QUINOLINE DERIVATIVES AS ANTIPSYCHOTIC AND ANTI OBESITY AGENTS | WYETH CORP (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20060154920-A1 | 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij] quinoline derivatives as antipsychotic and antiobesity agents | WYETH (US) | 2006-07-13 | — | — | US | disclosed |
| US-7071185-B2 | 1,2,3,4,7,8-hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents | WYETH (US) | 2006-07-04 | — | — | US | disclosed |
| EP-1497294-A1 | 1,2,3,4,7,8-HEXAHYDRO-6 i H /i - 1,4 DIAZEPINO 6,7 ,1- i 1J /i QUINOLINE DERIVATIVES AS ANTIPSYCHOTIC AND ANTI OBESITY AGENTS | Wyeth (US) | 2005-01-19 | — | — | EP | disclosed |
| US-20040019040-A1 | 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents | WYETH | 2004-01-29 | — | — | US | disclosed |
| WO-2003091251-A1 | 1,2,3,4,7,8-HEXAHYDRO-6H-[1,4]DIAZEPINO[6,7,1-1J]QUINOLINE DERIVATIVES AS ANTIPSYCHOTIC AND ANTIOBESITY AGENTS | WYETH (US) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154920-A1 | 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij] quinoline derivatives as antipsychotic and antiobesity agents | HTR2C, HTR7, HTR1A | FBP1 968/4885VCP 3879/4885TLR4 2625/4885 |
| US-20040019040-A1 | 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents | HTR2C, HTR1A, HTR7 | FBP1 653/4885VCP 3841/4885TLR4 2551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.